Real-world safety of linaclotide in Chinese patients with irritable bowel syndrome with constipation: a multicenter, single-arm, prospective observational study.

This finding is consistent with the results of the aforementioned Chinese sub-cohort analysis, where the mean treatment satisfaction demonstrated an increasing trend from baseline to week 12. 22 At week 12, 62.3% of patients with available treatment satisfaction data for this timepoint in our study were quite or very satisfied with linaclotide treatment, which was somewhat higher than that reported in the previous North American trial (52%). 20 Therefore, our study further reinforces existing evidence, highlighting the positive impact of linaclotide on improving treatment satisfaction in patients with IBS-C.

also in 63,971 other papers